Ocular Therapeutix™ Reports Third Quarter 2016 Financial Results and Provides Corporate Update

BEDFORD, Mass.--(BUSINESS WIRE)--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced financial results for the third quarter ended September 30, 2016 and provided a general business update. “Following productive discussions with the FDA, we are preparing for the resubmission of our NDA for DEXTENZA™ for post-surgical ocular pain by the end of the year,